media-valley-medicon-1.html
Medicon Valley_dec-jan
2 / 16
ispe marks 10-year anniversary announces
new
gala celebration during the society’s 2014 pharmaceutical quality week as the awards
program
enters its second decade after 10 years of setting the standard, ispe announced that it has made signifi cant enhancements to its annual facility of the year awards (foya)
program
, the premier global awards
program
focused on recognizing the innovation and creativity in manufacturing facilities serving the regulated healthcare industry. these enhancements are designed to celebrate the tenth anniversary of this distinguished awards
program
and include a
new
gala to recognize category winners at the annual ispe-fda cgmp conference (part of ispe’s
new
ly created pharmaceutical quality week) and an expanded presence for category winners at the ispe annual meeting. the quest for excellence - over the past decade, the pharmaceutical and biopharmaceutical industry has made signifi cant advancements in the technology and processes used in building and renova- ting manufacturing facilities, said nancy berg, ispe president and ceo. - these advancements refl ect the industry’s quest for excellence and superior product quality. as the premier awards
program
focused on recognizing these achievements, it is only fi tting that the facility of the year awards also make advancements in the way it showcases the category winners’ momentous accomplishments. by bringing the annual celebratory events for foya to pharmaceuti- cal quality week and the ispe annual meeting, ispe will present these innovative facilities to a global audience of top pharma- ceutical leaders and regulators. the 2014 awards
program
is now accepting entries through 3 february 2014. category award winners will be recognized in june in six categories: operational excellence, project execution, equipment innovation, process innovation, sustainability, and facility integration. companies interested in submit- ting their
new
ly constructed or renovated facilities for the 2014 foya
program
can fi nd complete eligibility criteria,
program
timelines and required entry forms at www.facilityoft- heyear.org/submityourfacility. facility of the year awards
program
sponsored by ispe, the facility of the year awards (foya) is an annual
program
recognizing state-of-the-art pharmaceutical manufacturing projects that utilize
new
and innovative technologies to enhance the delivery of a superior project, as well as reduce the cost of producing high-quality medicines. join forces to further enhance diabetes
research
oxford university and novo nordisk has announced the establishment of an international fellowship
program
me that aims to support the career and scientifi c development of young, excep- tional
research
talent within diabetes the partnership will establish a number of postdoctoral fellowship opportunities that will be hosted by oxford university and funded by novo nordisk. - we are honoured to establish the internatio- nal postdoctoral fellowship
program
me with oxford university, which has such valuable expertise in the study and treatment of diabetes. by combining our company’s discovery and clinical development strengths with the
research
expertise and academic tradition of oxford university, we can support the development of a
new
generation of exceptional diabetes
research
ers to eventually drive innovation further and improve the lives of the patients, said mads krogsgaard thomsen, executive vice president and chief science offi cer at novo nordisk. a
new
generation of
research
leaders as part of the agreement, a total of 12 young leading
research
ers will be offered a 3-year grant to support their
research
within the fi elds of diabetes, metabolism and endocrino- logy. the goal of the
new
program
me is to support the development of a
new
generation of
research
leaders while further developing scientifi c excellence within diabetes. - this
new
program
me will support the best young
research
ers doing novel work in the understanding of diabetes and its treatment. it is these early career
research
ers that will produce the
new
ideas, discoveries and advances that will improve diabetes treatment and care in the future. we’re delighted to partner with novo nordisk to provide this level of funding and support which will be important in enabling both their
research
and their career development, said professor hugh watkins of the radcliffe department of medicine at oxford university. a joint steering committee with members from both oxford university and novo nordisk will oversee the
program
me and assess
research
proposals from scientists at both organisations. the fi rst four fellows in the
program
me will start in the autumn of 2014.
new
ambitious center delves into protein drugs of the future designing
new
drugs based on the body’s own molecules will be the focus of a
new
center for biopharmaceuticals that was launched at the faculty of health and medical sciences on 1 november. the center will help solve the pharmaceutical challenges of the future in the fi eld of biological drugs the center for biopharmaceuticals will be a pioneering force in technologies that combine the principles and tools of chemistry with the synthetic strategies and processes of living organisms to create proteins with completely novel properties. the center will build on the strong multi-disciplinary relationship between the faculty of health and medical sciences’ two pharmaceutical departments, the department of drug design and pharmacology and the department of pharmacy. protein drugs are based on nature’s own design. that’s a big plus, because it means they are in tune with the body’s own raw material. it means drugs with less severe side-effects. currently more than half of drugs that are being tested in clinical trials are so-called biopharmaceuticals – consisting of proteins, peptides of nucleic acids – and the number is rising steadily. - the ability to manipulate proteins, known as protein engineering, has paved the way for important breakthroughs in biotechnology and biomedicine. proteins can for instance target certain cell processes with very high precision – and drugs based on proteins or peptides enable
new
ways to treat many diseases, says ole thastrup, professor and head of the department of drug design and pharmaco- logy, faculty of health and medical sciences. pioneering
research
in chemical biology the center for biopharmaceuticals is an ambitious “beacon” at the forefront of pharmaceutical protein and peptide
research
. proteins play a fundamental role in biological processes. they consist of strings of amino acids – so-called peptides – composed of up to 20 different amino acids. the composition, structure and function of proteins are controlled by the genetic code. at the
new
center for biopharmaceuticals, bright minds from around the world will be looking into rewriting this universal code: - to bring about the next major leap forward in protein science, we need to break through one of the greatest barriers of conventional protein engineering – the ability to ‘write’ protein recipes using other ‘letters’ than those 20 that make up the genetic alphabet, says professor kristian strømgaard, who has been appointed director of the
new
center for biopharmaceuticals.
search-executive-talent-3.html